Skip to main content
Profile
About Us
Board of Directors
Management team
Founders
Shareholders
LEUKOTAC®
Medical need
LEUKOTAC® development
What is LEUKOTAC®?
Pipeline R&D
Immuno-Oncology
ELB021
ELB031
ELB041
ELB011 (ophthalmology)
Partners
News & events
Latest news
Careers
Join Elsalys
Search
English
Français
Latest news
Breadcrumb
Home
Latest news
Catégories d'actualités
LEUKOTAC® (inolimomab)
(3)
ELB011 (anti-CD160 ophtalmology)
(3)
ELB021 (anti-CD160 Oncology)
(3)
ELB031 (anti-TYRO3/MERTK Oncology)
(1)
ELB041 (anti-CD115 Oncology)
(1)
Finance & Corporate
(6)
ELSALYS BIOTECH expands its rights on CD160
Tue, 02/16/2016 - 17:00
Having acquired in June 2015 the assets of CD160 in the field of ophthalmology, ElsaLys Biotech strengthens its intellectual property an
Read more
ELSALYS BIOTECH announces the completion of the first instalment of a total fundraising amounting to € 5 million
Tue, 11/03/2015 - 17:00
IM Europe and Sofimac Partners are the main investors
Read more
The TYROMAB consortium, headed by ELSALYS BIOTECH, obtains 1.57 million euros from the single interministerial fund (fui)
Thu, 09/10/2015 - 17:00
Supported by ElsaLys Biotech, PX’Therapeutics, a subsidiary of the Aguettant group, and Centr
Read more
ELSALYS BIOTECH acquires a first-in-class antibody with a dual biological mechanism of action: anti-angiogenic and immuno-modulator
Thu, 07/02/2015 - 17:00
Developed so far by MABLIFE in ophthalmology, the anti-CD160 antibody has also a significant therapeutic potential in oncology.
Read more
Pagination
First page
« First
Previous page
‹ Previous
Page
1
Current page
2
STAY IN TOUCH WITH OUR LATEST NEWS
Subcribe to our newsletter
Subscribe now
Copyright 2018 ElsaLys Biotech SA